Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients with Relapsed or Refractory CD30-Positive Lymphomas

Next Previous
X
Search
Trial Profile

A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients with Relapsed or Refractory CD30-Positive Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TT 11X (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions
  • Acronyms BESTA

    • Most Recent Events

    • 30 May 2023 According to a Tessa Therapeutics media release, data from this study will be presented at the17th International Conference on Malignant Lymphoma.
    • 10 Dec 2022 Results published in the Tessa Therapeutics Media Release
    • 10 Dec 2022 According to a Tessa Therapeutics media release, enhanced clinical data from the study was presented at the 64th Annual Meeting of the American Society of Hematology (ASH).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top